Risperdal News and Research

RSS

Feds reject J & J's $1 billion drug settlement

Prosecutors in Washington, D.C., have rejected a roughly $1 billion proposed settlement to resolve allegations that Johnson & Johnson promoted the antipsychotic drug Risperdal for unapproved uses, according to people familiar with the matter.

13 Mar 2012

Weight gain or loss may also depend on medicines taken

Weight gain or loss may not always be caused by what you eat or how much you exercise. For some, it's the medicines you're taking.

22 Feb 2012

Genetic variation predisposes children to complications linked with second-generation anti-psychotics

Researchers have found a genetic variation predisposing children to six-times greater risk of developing metabolic syndrome when taking second-generation anti-psychotic medications. Metabolic syndrome is a cluster of conditions that are risk factors for cardiovascular disease.

25 Jan 2012

Risperdal lawsuit settlement: Largest Medicaid fraud case in Texas

Texas and Janssen Pharmaceuticals reach a $158 million settlement on a suit claiming that the company lied about the efficacy of the anti-psychotic medicine.

21 Jan 2012

Roundup: State lawmakers urge deficit reduction

On Wednesday, the National Conference of State Legislatures, which represents lawmakers from across the country, sent President Barack Obama, Speaker of the House John Boehner and Senate Majority Leader Harry Reid a letter urging them to "examine all possible avenues for deficit reduction, including discretionary spending, entitlement reform and revenue-related options."

20 Jan 2012

Roundup: Iowa weighs mental health care changes; Ariz. clinic seeks to cut ER costs

Republican and Democratic legislators and Gov. Terry Branstad have said they want to reform Iowa's mental health system to reduce waiting lists and provide more equitable services. Currently, each of Iowa's counties performs or contracts for mental health services for indigent residents. Critics contend the 99-county system has led to pockets of inferior, inequitable service, particularly in rural areas.

10 Jan 2012

Walgreen expecting sharp drop in prescription business

A contract dispute with pharmacy benefit manager Express Scripts is likely to cut the number of drugs Walgreen will sell.

23 Dec 2011

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

Alkermes, Inc. today announced positive topline results from a phase 1b, double-blind, randomized, placebo-controlled study of ALKS 9070 in patients with schizophrenia.

30 Jun 2011

State roundup: N.Y. and union reach deal on benefits

The state's largest public-employee union, acknowledging the pressures on government workers around the nation, agreed on Wednesday to major wage and benefits concessions in a pact to avoid sweeping layoffs. The five-year agreement ... includes a three-year wage freeze, the first furloughs ever for state workers and an increase in the amount employees must pay toward their health insurance.

24 Jun 2011

Risperidone recall by J&J

Ortho-McNeil-Janssen Pharmaceuticals Inc., a unit of Johnson & Johnson, recalled about 16,000 bottles of its Risperdal schizophrenia drug on reports of an uncharacteristic odor. The recall affects one lot that was shipped between Aug. 27, 2010, and Feb. 15, 2011.

19 Jun 2011

Mylan introduces Risperidone Orally Disintegrating Tablets for schizophrenia treatment

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Risperidone Orally Disintegrating Tablets, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg, the generic version of Ortho-McNeil's Risperdal M-Tab, a treatment for schizophrenia.

13 May 2011

Elan Drug Technologies, Alkermes merge to form new company in Ireland

Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million.

9 May 2011

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson today announced sales of $16.2 billion for the first quarter of 2011, an increase of 3.5% as compared to the first quarter of 2010.

19 Apr 2011

Risperdal Consta can reduce risk of hospitalisation in patients with schizophrenia

New data from an independent prospective study presented last week at the 19th European Congress of Psychiatry shows treatment with Risperdal Consta is associated with a lower risk of hospitalisation in patients with schizophrenia compared to treatment with other antipsychotics over a 12-month period.

5 Apr 2011

Non-generic drugs increase Medicaid costs

A new study by the American Enterprise Institute found that using brand-name drugs instead of generics may have added as much as $329 million in extra spending in 2009.

30 Mar 2011

Study reports significant decline in second-generation medication use for dementia

As loved ones with dementia disappear into symptoms of aggression, agitation or delusions, families are left with few good medical solutions. A new generation of antipsychotic medications gained popularly in the 1990s because they avoided side effects such as Parkinson's syndrome associated with conventional antipsychotic medications used to treat dementia.

8 Feb 2011

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson today announced sales of $15.6 billion for the fourth quarter of 2010, a decrease of 5.5% as compared to the fourth quarter of 2009. Operational sales declined 5.1% and the negative impact of currency was 0.4%. Domestic sales declined 8.1%, while international sales declined 3.1%, reflecting an operational decline of 2.3% and a negative currency impact of 0.8%.

25 Jan 2011

Research report on current and evolving technologies in drug delivery

The drug delivery market is a rapidly evolving force in the pharmaceutical industry. Within this segment injectables have a significant role to play at present with the increasing use of proteins and peptides.

9 Nov 2010

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson today announced sales of $15.0 billion for the third quarter of 2010, a decrease of 0.7% as compared to the third quarter of 2009. Operational results increased 0.1% and the negative impact of currency was 0.8%. Domestic sales declined 2.5%, while international sales increased 1.1%, reflecting operational growth of 2.6% and a negative currency impact of 1.5%.

19 Oct 2010

Policy restrictions for certain medications lead to decreased drug use and substantial savings for insurers

Policies that restrict reimbursement for certain medications can save money for health insurers without driving patients to seek other kinds of health care, a new review of studies suggests.

19 Aug 2010